Zhang CY, Yang M. Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. World J Hepatol 2022; 14(5): 956-971 [PMID: 35721293 DOI: 10.4254/wjh.v14.i5.956]
Corresponding Author of This Article
Ming Yang, DVM, PhD, Postdoctoral Fellow, Department of Surgery, University of Missouri, 1030 Hitt Street, NexGen Precision Building, Room 2203, Columbia, MO 65211, United States. yangmin@health.missouri.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 27, 2022; 14(5): 956-971 Published online May 27, 2022. doi: 10.4254/wjh.v14.i5.956
Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis
Chun-Ye Zhang, Ming Yang
Chun-Ye Zhang, Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, United States
Ming Yang, Department of Surgery, University of Missouri, Columbia, MO 65211, United States
Author contributions: Zhang CY and Yang M conceived the idea for this study and collected and analyzed the data, wrote, finalized the manuscript letter, and contributed equally; All authors approved the submitted version and published version.
Institutional review board statement: This study was performed without animal and human studies.
Institutional animal care and use committee statement: This study was performed without animal and human studies.
Conflict-of-interest statement: Both authors declared that there was no conflict of interest with the content of this study.
Data sharing statement: All the data analyzed in this study originated from publicly available The Cancer Genome Atlas database (TCGA Research Network: https://www.cancer.gov/tcga).
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming Yang, DVM, PhD, Postdoctoral Fellow, Department of Surgery, University of Missouri, 1030 Hitt Street, NexGen Precision Building, Room 2203, Columbia, MO 65211, United States. yangmin@health.missouri.edu
Received: December 31, 2021 Peer-review started: December 31, 2021 First decision: February 21, 2022 Revised: March 1, 2022 Accepted: May 7, 2022 Article in press: May 7, 2022 Published online: May 27, 2022 Processing time: 143 Days and 17.1 Hours
Core Tip
Core Tip: Liver cancer ranks the third cause of cancer-related death worldwide. The most common type of liver cancer is hepatocellular carcinoma (HCC). Lack of effective treatment options and early diagnostic biomarkers results in a short survival time of HCC patients. Ubiquitination plays an essential role in the biochemical processes in cells. In this study, using bioinformatic analysis of the online TCGA database we found that three ubiquitin-conjugating enzyme 2 (UBE2) genes were overexpressed in HCC samples compared to normal samples in a stage-dependent manner, including UBE2C, UBE2T, and UBE2S. Additionally, overexpression of those genes was negatively associated with prognostic outcomes and overall survival times. Patients with TP53 mutation showed a higher level of expression of three UBE2 genes, indicating an association between UBE2 expression with p53 function. This study shed light on the potential roles of UBE2C, UBE2T, and UBE2S on diagnostic and prognostic biomarkers for HCC, as well as the therapeutic strategy.
